Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Victor Moyo
Safety and Pharmacokinetics of MM-302, a HER2-targeted Antibody–liposomal Doxorubicin Conjugate, in Patients With Advanced HER2-positive Breast Cancer: A Phase 1 Dose-Escalation Study
British Journal of Cancer
Cancer Research
Oncology
Related publications
Targeted Therapy for HER2 Positive Breast Cancer
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Prospective Evaluation of the Cardiac Safety of HER2-targeted Therapies in Patients With HER2-positive Breast Cancer and Compromised Heart Function: The SAFE-HEaRt Study
Breast Cancer Research and Treatment
Cancer Research
Oncology
Efficacy and Safety of HER2-Targeted Agents for Breast Cancer With HER2-Overexpression: A Network Meta-Analysis
PLoS ONE
Multidisciplinary
BioPATH: A Biomarker Study in Asian Patients With HER2+ Advanced Breast Cancer Treated With Lapatinib and Other Anti-Her2 Therapy
Cancer Research and Treatment
Cancer Research
Oncology
Targeted Delivery of Doxorubicin to HER2 Positive Tumor Models
International Journal of Nanomedicine
Organic Chemistry
Biophysics
Biomaterials
Pharmaceutical Science
Medicine
Bioengineering
Drug Discovery
Nanoscience
Nanotechnology
A Phase I/Ii Study of Poziotinib Combined With Paclitaxel and Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer
Gastric Cancer
Cancer Research
Medicine
Oncology
Gastroenterology
Antibody–Drug Conjugate Hits Elusive HER2 + Breast Tumors
Cancer Discovery
Oncology
A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination With Erlotinib in Patients With Advanced Solid Tumors
Oncologist
Cancer Research
Medicine
Oncology
Phase I Study of Intermittent High Dose Lapatinib Alternating With Capecitabine for HER2-positive Breast Cancer Patients With Central Nervous System Metastases
Clinical Cancer Research
Cancer Research
Oncology
